Search Results 51-60 of 16626 for villous atrophy
Mayo Clinic researchers study risk factors, predictors, diagnostic techniques and potential treatments for posterior cortical atrophy, Alzheimer's disease and ...
About this study. To evaluate whether SSRI use is associated with increased survival time and slower disease progression among patients with MSA.
... Investigators. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
Dominant optic atrophy. Friedreich's ataxia. Hereditary paraganglioma. Hereditary spastic paraplegia. Kearns-Sayre syndrome. Leber hereditary optic ...
Learn more about this heart condition that causes the walls of the heart's main pumping chamber to become enlarged and thickened.
By comparing the gene expression of motor neurons derived from iPSC cells of phenotypically discordant Spinal Muscular Atrophy (SMA) sibling pairs and ...
... Atrophy Rating Scale (UMSARS) Part I, minus the sexual function item, with collapse of the normal and mild ratings on each item. Participation eligibility.
Types · Retinal tear. · Retinal detachment. · Diabetic retinopathy. · Epiretinal membrane. · Macular hole. · Macular degeneration. · Retinitis pigmentosa.
A wheat allergy does not equal celiac disease. The wheat allergy is a very rapid response, very much like the other allergies. Celiac disease is more of a slow ...
The purpose of this study is to compare the effectiveness of BHV-3241 versus placebo in subjects with Multiple System Atrophy. Participation eligibility.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.